Article

S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells

Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany.
Molecular biology of the cell (Impact Factor: 5.98). 07/2011; 22(18):3344-54. DOI: 10.1091/mbc.E10-09-0739
Source: PubMed

ABSTRACT The calcium-binding protein S100A4 is a central mediator of metastasis formation in colon cancer. S100A4 is a target gene of the Wnt/β-catenin pathway, which is constitutively active in the majority of colon cancers. In this study a high-throughput screen was performed to identify small-molecule compounds targeting the S100A4-promoter activity. In this screen calcimycin was identified as a transcriptional inhibitor of S100A4. In colon cancer cells calcimycin treatment reduced S100A4 mRNA and protein expression in a dose- and time-dependent manner. S100A4-induced cellular processes associated with metastasis formation, such as cell migration and invasion, were inhibited by calcimycin in an S100A4-specific manner. Calcimycin reduced β-catenin mRNA and protein levels despite the expression of Δ45-mutated β-catenin. Consequently, calcimycin inhibited Wnt/β-catenin pathway activity and the expression of prominent β-catenin target genes such as S100A4, cyclin D1, c-myc, and dickkopf-1. Finally, calcimycin treatment of human colon cancer cells inhibited metastasis formation in xenografted immunodeficient mice. Our results demonstrate that targeting the expression of S100A4 with calcimycin provides a functional strategy to restrict cell motility in colon cancer cells. Therefore calcimycin may be useful for studying S100A4 biology, and these studies may serve as a lead for the development of treatments for colon cancer metastasis.

0 Followers
 · 
328 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent technological advances have significantly improved our understanding of tumor biology by means of high-throughput mutation and transcriptome analyses. The application of genomics has revealed the mutational landscape and the specific deregulated pathways in different tumor types. At a transcriptional level, multiple gene expression signatures have been developed to identify biologically distinct subgroups of tumors. By supervised analysis, several prognostic signatures have been generated, some of them being commercially available. However, an unsupervised approach is required to discover a priori unknown molecular subtypes, the so-called intrinsic subtypes. Moreover, an integrative analysis of the molecular events associated with tumor biology has been translated into a better tumor classification. This molecular characterization confers new opportunities for therapeutic strategies in the management of cancer patients. However, the applicability of these new molecular classifications is limited because of several issues such as technological validation and cost. Further comparison with well-established clinical and pathological features is expected to accelerate clinical translation. In this review, we will focus on the data reported on molecular classification in the most common tumor types such as breast, colorectal and lung carcinoma, with special emphasis on recent data regarding tumor intrinsic subtypes. Likewise, we will review the potential applicability of these new classifications in the clinical routine.
    Cellular Oncology 01/2015; 38(1). DOI:10.1007/s13402-014-0203-7 · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In humans, the S100 protein family is composed of 21 members that exhibit a high degree of structural similarity, but are not functionally interchangeable. This family of proteins modulates cellular responses by functioning both as intracellular Ca(2+) sensors and as extracellular factors. Dysregulated expression of multiple members of the S100 family is a common feature of human cancers, with each type of cancer showing a unique S100 protein profile or signature. Emerging in vivo evidence indicates that the biology of most S100 proteins is complex and multifactorial, and that these proteins actively contribute to tumorigenic processes such as cell proliferation, metastasis, angiogenesis and immune evasion. Drug discovery efforts have identified leads for inhibiting several S100 family members, and two of the identified inhibitors have progressed to clinical trials in patients with cancer. This Review highlights new findings regarding the role of S100 family members in cancer diagnosis and treatment, the contribution of S100 signalling to tumour biology, and the discovery and development of S100 inhibitors for treating cancer.
    Nature reviews. Cancer 01/2015; 15(2):96-109. DOI:10.1038/nrc3893 · 37.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Expression of the small calcium-binding protein S100A4 is associated with poor prognosis in patients with thyroid cancer (TC). We have shown that S100A4 is a target for relaxin and insulin-like peptide 3 (INSL3) signaling in TC cells and that S100A4 is secreted from human TC cells. Although the pro-migratory role of intracellular S100A4 in binding to non-muscle myosin is well known, we investigated here whether extracellular S100A4 contributes to TC migration. Methods: We utilized human cell lines of follicular (FTC), papillary (PTC), undifferentiated (UTC) thyroid cancer, primary patient TC cells and TC tissues to discover the presence of RAGE in TC cells and TC tissues. We used fluorescence imaging, protein pull-down assays, Western blot, siRNA protein silencing, small GTPase inhibitors, cell proliferation and cell migration assays to investigate the interaction of extracellular S100A4 with RAGE in promoting a TC migratory response. Results: We demonstrated that RAGE serves as receptor for extracellular S100A4 mediating cell migration in TC cells. The RAGE-mediated increase in cell migration is dependent on the intracellular RAGE signaling partner diaphanous-1 (DIA-1) and involves the activation of the small GTPases CDC42 and RHOA. Although extracellular S100A4 consistently activates ERK signaling in TC cells, we show that ERK signaling is not mediated by RAGE and not essential for the migratory response in TC cells. Conclusion: Our data have identified the RAGE/ -DIA-1 signaling system as a mediator for the pro-migratory response of extracellular S100A4 in human thyroid cancer. Thus, therapeutic targeting of the RAGE/DIA-1/small GTPases signaling may successfully reduce local invasion and metastasis in thyroid cancer.
    Thyroid 03/2015; · 3.84 Impact Factor